Alessandro Laganà

12PUBLICATIONS
10CO-AUTHORS
Molecular targetsPredictive and prognostic markersRespiratory diseasesMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 26, 2026
Four Decades of Molecular Innovation in Chronic Myeloid Leukemia: From Antisense Targeting to Treatment-Free Remission.

|Nov 20, 2025
Early predictive factors of molecular relapse in chronic phase-chronic myeloid leukemia (CP-CML) patients after tyrosine kinase inhibitor (TKI) discontinuation.

Alessandro Laganà, Emilia Scalzulli, Ida Carmosino

|Oct 16, 2025
Increased Rate of Anemia and Discontinuation in Older Patients with Myelofibrosis Treated with Ruxolitinib.

Alessandro Laganà, Emilia Scalzulli, Ida Carmosino

|Sep 08, 2025
Clinical Relevance and Prognostic Value of the Triple A (AAA) Score in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX).

Alessandro Laganà, Emilia Scalzulli, Maria Laura Bisegna

|Jun 30, 2025
Treatment Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML): Analysis of Predictive Factors and Novel Baseline Scoring System to Predict Molecular Relapse.

Alessandro Laganà, Emilia Scalzulli, Ida Carmosino

|Apr 28, 2025
CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITDmut-AML): a flow-cytometric marker for an accurate diagnostic workup.

Alessandro Laganà, Deborah Kasmi, Daniela Diverio

Pageof 2

Frequent Collaborators

10 joint publications

Massimo Breccia

4 joint publications

Claudia Ielo

2 joint publications

Alessandro Costa

1 joint publications

Chiara Masucci